申请人:Agouron Pharmaceuticals, Inc.
公开号:US20040053922A1
公开(公告)日:2004-03-18
Metabolites of a matrix metalloproteinase inhibitor prinomastat and their synthesis. These metabolites are: (3S)-N-hydroxy4-(4-((1-oxy-pyrid-4-yl)oxy)benzenesulfonyl)-2,2-dimethyl-tetrahydro-2H-1,4-thiazine-3-carboxamide (M6); (3S)-2,2-dimethyl-1,1-dioxo-4-[4-(1-oxy-pyridin-4-yloxy)-benzenesulfonyl]-thiomorpholine-3-carboxylic acid amide (M7); (3S)-2,2-dimethyl-4-[4-(1-oxypyridin-4-yloxy)-benzenesulfonyl]-thiomorpholine-3-carboxylic acid amide (M8); (3S)-2,2-dimethyl-1,1-dioxo-4-[4-(pyridin-4-yloxy)-benzenesulfonyl]-thiomorpholine-3-carboxylic acid amide (M2); and (3S)-2,2-dimethyl-4-[4-(pyridin-4yloxy)-benzenesulfonyl)-thiomorphpline-3-carboxylic acid amide (M3).
基质金属蛋白酶抑制剂普利诺马斯塔的代谢产物及其合成方法。这些代谢产物包括:(3S)-N-羟基-4-(4-((1-氧基-吡啶-4-基)氧基)苯磺酰基)-2,2-二甲基-四氢-2H-1,4-噻嗪-3-羧酰胺(M6);(3S)-2,2-二甲基-1,1-二氧化-4-[4-(1-氧基-吡啶-4-基氧基)苯磺酰基]噻吗啉-3-羧酸酰胺(M7);(3S)-2,2-二甲基-4-[4-(1-氧基-吡啶-4-基氧基)苯磺酰基]噻吗啉-3-羧酸酰胺(M8);(3S)-2,2-二甲基-1,1-二氧化-4-[4-(吡啶-4-基氧基)苯磺酰基]噻吗啉-3-羧酸酰胺(M2);和(3S)-2,2-二甲基-4-[4-(吡啶-4-基氧基)苯磺酰基]噻吗啉-3-羧酸酰胺(M3)。